Mode
Text Size
Log in / Sign up

Multiomics analysis reveals sustained immune dysregulation in pediatric MIS-C patients compared to healthy controls.

Multiomics analysis reveals sustained immune dysregulation in pediatric MIS-C patients compared to h…
Photo by Nigel Hoare / Unsplash
Key Takeaway
Note sustained cytokine elevation and cross-reactive TCRs in MIS-C, suggesting prolonged autoimmunity without established causality.

This study utilized a multiomics approach to analyze plasma and peripheral immune cells from 13 acute MIS-C patients, 18 recovered MIS-C follow-ups, and 15 healthy pediatric controls. The investigation aimed to characterize the immune landscape during the acute phase and during recovery, extending up to 18 months post-onset. No specific medications were administered as part of the intervention, serving instead to observe natural disease progression and immune resolution.

Results indicated persistent immune activation in the MIS-C cohort. Circulating pro-inflammatory cytokines, including IL-8, IL-6, IL-1, IL-1{beta}, and TNF-{beta}, remained elevated up to three months after MIS-C onset. Similarly, circulating TH2-type cytokines such as IL-4, IL-5, and IL-13 showed sustained elevation during the same period. Furthermore, 75% (12 of 16) of the identified SARS-CoV-2 TCRs demonstrated cross-reactivity with autoantigens. Autoantibodies were elevated across 13 gene targets involving self-antigen peptides, and autoreactive TCR expansions persisted over time, correlating with cytokines involved in allergic inflammation.

Safety and tolerability data were not reported in this observational study. A key limitation is that few details regarding the underlying disease pathology have been resolved. Consequently, while findings point to a mechanism of sustained autoimmunity, the evidence is observational and does not establish causality. The study did not report adverse events, discontinuations, or specific funding conflicts. Clinicians should interpret these immunological markers as indicators of prolonged immune dysregulation in MIS-C recovery, noting that the data lacks statistical precision and detailed pathological context.

Study Details

EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Multisystem inflammatory syndrome in children (MIS-C) is a pediatric hyperinflammatory disease manifesting 4-6 weeks after SARS-CoV-2 infection. While the immunological hallmarks of MIS-C have been defined, few details regarding the underlying disease pathology have been resolved. To address this, we used a multiomics approach to profile the plasma and peripheral immune cells of 13 acute MIS-C patients, 18 recovered MIS-C follow-ups resampled over multiple time points (1-18 months), and 15 healthy pediatric controls. Despite rapid clinical disease resolution, circulating pro-inflammatory (IL-8, IL-6, IL-1, IL-1{beta}, TNF-{beta}) and TH2-type cytokines (IL-4, IL-5, IL-13) remained elevated up to three months post-MIS-C onset, revealing a subclinical inflammatory state that endures in recovered children. Surprisingly, the majority of patient-expanded TCRs recognizing SARS-CoV-2 epitopes were cross-reactive (75%, 12/16 SARS-CoV-2 TCRs) for autoantigens related to prostaglandin biology and insulin metabolism, suggesting a breakdown of self-tolerance via SARS-CoV-2 molecular mimicry. Indeed, autoantibody screening confirmed that 13 gene targets with self-antigen peptides also exhibited elevated autoantibodies in MIS-C patients. Further, autoreactive TCR expansions lasted over time and correlated with cytokines involved in allergic inflammation. Together, our findings point to a mechanism of sustained autoimmunity wherein promiscuous TCRs recognize both viral and self-antigens that are activated during primary SARS-CoV-2 infection in children who develop MIS-C. Upon onset, these circulating cross-reactive T cells drive clinically apparent sterile autoinflammation that persists subclinically into convalescence.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.